Group 1 - The global biopharmaceutical industry is increasingly investing in the Chinese market, making the healthcare sector a hot investment area [2] - In 2024, Danish company Novo Nordisk announced an investment of approximately 4 billion RMB in Tianjin [2] - In July of this year, Novo Nordisk also announced an investment of around 800 million RMB to expand its quality testing laboratory in Tianjin [2]